Second-line chemotherapy for patients with oesophagogastric adenocarcinoma
Menée sur 168 patients atteints d'un adénocarcinome de l'œsophage, de la jonction œso-gastrique ou de l'estomac réfractaire aux sels de platine et aux fluoropyrimidines, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du docétaxel en traitement de deuxième ligne
During the past two decades, there have been major advancements in cancer treatment, such as the incorporation of newer cytotoxic, molecularly targeted, and other biological agents to traditional chemotherapy. Unfortunately, clinical trials involving novel agents have had little success in the treatment of oesophagogastric adenocarcinoma, which is one of the main causes of cancer-related deaths worldwide. Initial reports of chemotherapy regimens that include fluoropyrimidines, anthracyclines, or ...
The Lancet Oncology , commentaire, 2012